Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

FDA Greenlights Life Biosciences’ Human Study, Setting Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

…Life Biosciences, a biotech company co-founded by Sinclair, received the FDA’s approval to begin a human trial testing its gene therapy based on the Information Theory of Aging. The gene therapy is designed to rewind the clock and restore the function of dying cells…

…Life Biosciences’ gene therapy has been under development for quite a while. In the 1990s, David Sinclair first contended that the deterioration and loss of epigenetic information—chemical tagging patterns on DNA that regulate which genes are turned on and off—plays an important role in driving aging. Sinclair subsequently dubbed this contention the Information Theory of Aging. Fast forward to the present day, and Life Biosciences has produced a gene therapy that delivers three proteins, which Sinclair’s laboratory helped establish, to reset epigenetic information to a more youthful state.

‘It’s extremely exciting,’ Sinclair told Endpoints News. ‘It’s been over 30 years to get to this point, and we’re about to learn if all of that work is going to come to fruition this year.’


The FDA has greenlighted Life Biosciences’ first human trial testing whether their gene therapy can confer a near-total rejuvenating reset of cells.

Virus-based therapy boosts anti-cancer immune responses to brain cancer

A team led by investigators has shown that a single injection of an oncolytic virus—a genetically modified virus that selectively infects and destroys cancer cells—can recruit immune cells to penetrate and persist deep within brain tumors. The research, which is published in Cell, provides details on how this therapy prolonged survival in patients with glioblastoma, the most common and malignant primary brain tumor, in a recent clinical trial.

The oncolytic virus used in the team’s trial is made from a herpes simplex virus genetically altered so it can only make copies of itself in glioblastoma cells and not normal healthy cells. The virus spreads to a glioblastoma cell, kills it, and then makes a copy of itself that spreads again to another glioblastoma cell. Infection of cells with the virus also triggers an immune response. In the phase 1 trial of 41 patients with recurrent glioblastoma, the oncolytic virus treatment extended survival compared to historically reported survival, especially among those with pre-existing viral antibodies.

In their Cell study, the investigators examined the extent of this immune response in clinical trial participants. Their analysis revealed that the treatment induced long-term infiltration of immune T cells into patients’ tumors. Closer proximity of cytotoxic T cells with dying brain tumor cells was associated with longer patient survival after treatment. The therapy also expanded pre-existing T cells in the brain. ScienceMission sciencenewshighlights.

Rapid Evolution of Complex Multi-mutant Proteins

The researchers developed MULTI-evolve, a framework for efficient protein evolution that applies machine learning models trained on datasets of ~200 variants focused specifically on pairs of function-enhancing mutations.

Published in Science, this work represents the first lab-in-the-loop framework for biological design, where computational prediction and experimental design are tightly integrated from the outset, reflecting our broader investment in AI-guided research.

Our insight was to focus on quality over quantity. First identify ~15–20 function-enhancing mutations (using protein language models or experimental screens), then systematically test all pairwise combinations of those beneficial mutations. This generates ~100–200 measurements, and every one is informative for learning beneficial epistatic interactions.

We validated this computationally using 12 existing protein datasets from published studies. Training neural networks on only the single and double mutants, we found models could accurately predict complex multi-mutants (variants with 3–12 mutations) across all 12 diverse protein families. This result held even when we reduced training data to just 10% of what was available.

Training on double mutants works because they reveal epistasis. A double mutant might perform better than the sum of its parts (synergy), worse than expected (antagonism), or exactly as predicted (additivity). These pairwise interaction patterns teach models the rules for how mutations combine, enabling extrapolation to predict which 5-, 6-, or 7-mutation combinations will work synergistically.

We then applied MULTI-evolve to three new proteins: APEX (up to 256-fold improvement over wild-type, 4.8-fold beyond already-optimized APEX2), dCasRx for trans-splicing (up to 9.8-fold improvement), and an anti-CD122 antibody (2.7-fold binding improvement to 1.0 nM, 6.5-fold expression increase). For dCasRx, we started with a deep mutational scan of 11,000 variants, extracted only the function-enhancing mutations, and tested their pairwise combinations—demonstrating the value of strategic data curation for efficient engineering.

Each required experimentally testing only ~100–200 variants in a single round to train models that accurately predicted complex multi-mutants, compressing what traditionally takes 5–10 iterative cycles over many months into weeks. Science Mission sciencenewshighlights.

At our upcoming conference

we are thrilled to host Joscha Bach at Future Day 2026 – he is a leading voice in cognitive architectures and the founding director of the California Institute for Machine Consciousness. Bach’s talks are famous for being mind-bending journeys that challenge fundamental assumptions about reality and agency. In his upcoming session, he will dive into the Machine Consciousness Hypothesis, offering a glimpse into how we might one day create truly sentient digital minds.


Joscha Bach – The Machine Consciousness Hypothesis.

What if our consciousness is not a ‘thing’ we have, but a simulation our brain runs to make sense of itself?

We’ve Been Invaded By Aliens… Now What?

If aliens invaded, how would humanity respond? From planetary defense and space warfare to unexpected diplomatic twists, we’ll explore the strategies, technologies, and scenarios that could decide our fate.

Watch my exclusive video Post-Consciousness Civilizations: https://nebula.tv/videos/isaacarthur–
Get Nebula using my link for 40% off an annual subscription: https://go.nebula.tv/isaacarthur.
Get a Lifetime Membership to Nebula for only $300: https://go.nebula.tv/lifetime?ref=isa
Use the link gift.nebula.tv/isaacarthur to give a year of Nebula to a friend for just $30.

Visit our Website: http://www.isaacarthur.net.
Join Nebula: https://go.nebula.tv/isaacarthur.
Support us on Patreon: / isaacarthur.
Support us on Subscribestar: https://www.subscribestar.com/isaac-a
Facebook Group: / 1583992725237264
Reddit: / isaacarthur.
Twitter: / isaac_a_arthur on Twitter and RT our future content.
SFIA Discord Server: / discord.
Credits:
We’ve Been Invaded By Aliens… Now What?
Episode 494a; April 13, 2025
Written, Produced & Narrated by: Isaac Arthur.
Edited by: Ludwig Luska.
Graphics: Jeremy Jozwik, Ken York YD Visual, Legiontech Studios.
Select imagery/video supplied by Getty Images.
Music Courtesy of Epidemic Sound http://epidemicsound.com/creator.
Sergey Cheremisinov, \

RNA-binding proteins and ribonucleoproteins as determinants of immunity

RNA-binding proteins (RBPs) considerably expand the information content of the genome and can determine the lifespan, localization and function of RNA, thereby controlling when, where and how much protein is produced. There is a growing body of evidence that links RBPs to specialized functions of immune cells and they can also mediate cell-autonomous immunity to foreign RNA and to misfolded self-RNAs. This Review examines how RBPs regulate the biogenesis and fate of mRNAs to mediate immune cell function and cell-autonomous immunity and their roles in immunodeficiency, autoimmunity and chronic inflammation.

Scientists Create Chip That Generates Brand-New Colors of Light, Cracking a Decades-Old Nonlinear Optics Challenge

For decades, scientists and engineers have steadily advanced technologies that control and manipulate light. These tools now underpin everything from ultra-precise atomic clocks to the massive data flows moving through modern data centers.

As industries increasingly rely on optical systems, the market for dependable light-based technologies has grown into a sector worth hundreds of billions of dollars worldwide.

The Secret to Fighting Alzheimer’s May Be Hiding in Your Muscles

The study’s findings suggest that the key to combating Alzheimer’s disease may lie not only in the brain but also in our muscles. Alzheimer’s disease (AD) is a progressive condition marked by memory loss and declining cognitive function, and there is still no cure. Among the many factors that inf

Securing the Cyber Supply Chain in an AI Era

Supply chain attacks are now a top cyber threat—SolarWinds and Colonial Pipeline showed how one weak link can cascade across entire sectors.

In my latest article, I examine how AI, 5G, IoT, and quantum computing are expanding both risks and defenses, and share practical steps: zero trust, SBOMs, supplier audits, public-private collaboration, and board-level ownership.

Cyber supply chain security is no longer optional—it’s essential for resilience, innovation, and national security.

Read the full piece: The Cybersecurity Challenges of the Supply Chain https://www.govconwire.com/articles/chuck-brooks-govcon-expe…hain-risks.

#cybersecurity #technology #supplychain


By Chuck Brooks, president of Brooks Consulting International and one of Executive Mosaic’s GovCon Experts

/* */